To evaluate changes in thyroid function among patients with early luminal breast cancer receiving adjuvant endocrine therapy compared to those with benign breast disease (BBD).
Key Findings:
The BC group showed a significant increase in TSH (from 1.92 to 3.06 μIU/mL) and decreases in FT3 (from 4.90 to 4.14 pmol/L) and FT4 (from 18.35 to 15.26 pmol/L) after 3 years.
The BBD group showed no statistically significant changes over time.
Significant group-by-time interactions were found for TSH (P = 0.018), FT3 (P = 0.016), and FT4 (P < 0.001).
In subgroup analysis, a significant interaction was observed for FT4 (P = 0.022) with greater decline in FT4 with TAM.
Interpretation:
Adjuvant endocrine therapy in early luminal breast cancer was associated with statistically significant alterations in thyroid function over 3 years.
Limitations:
Small sample size.
Complete collinearity between treatment type and menopausal status limits conclusions regarding differential effects of TAM versus AIs.
Conclusion:
Further prospective studies are warranted to validate these observations and explore their potential clinical relevance.
